209 related articles for article (PubMed ID: 32369506)
1. Sex-specific cardiac remodeling in early and advanced stages of hypertrophic cardiomyopathy.
Nijenkamp LLAM; Bollen IAE; Niessen HWM; Dos Remedios CG; Michels M; Poggesi C; Ho CY; Kuster DWD; van der Velden J
PLoS One; 2020; 15(5):e0232427. PubMed ID: 32369506
[TBL] [Abstract][Full Text] [Related]
2. Sex Differences at the Time of Myectomy in Hypertrophic Cardiomyopathy.
Nijenkamp LLAM; Bollen IAE; van Velzen HG; Regan JA; van Slegtenhorst M; Niessen HWM; Schinkel AFL; Krüger M; Poggesi C; Ho CY; Kuster DWD; Michels M; van der Velden J
Circ Heart Fail; 2018 Jun; 11(6):e004133. PubMed ID: 29853478
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of R403WMYH7 and R92WTNNT2 HCM families: mutations determine left ventricular dimensions but not wall thickness during disease progression.
Revera M; Van der Merwe L; Heradien M; Goosen A; Corfield VA; Brink PA; Moolman-Smook JC
Cardiovasc J Afr; 2007; 18(3):146-53. PubMed ID: 17612745
[TBL] [Abstract][Full Text] [Related]
4. Coronary telangiectasia associated with hypertrophic cardiomyopathy.
Frustaci A; Lanfranchi G; Bellin M; Chimenti C
Eur J Heart Fail; 2012 Dec; 14(12):1332-7. PubMed ID: 22869457
[TBL] [Abstract][Full Text] [Related]
5. Fropofol prevents disease progression in mice with hypertrophic cardiomyopathy.
Huang Y; Lu H; Ren X; Li F; Bu W; Liu W; Dailey WP; Saeki H; Gabrielson K; Abraham R; Eckenhoff R; Gao WD
Cardiovasc Res; 2020 May; 116(6):1175-1185. PubMed ID: 31424496
[TBL] [Abstract][Full Text] [Related]
6. Left ventricular outflow tract gradient is associated with reduced capillary density in hypertrophic cardiomyopathy irrespective of genotype.
Güçlü A; Happé C; Eren S; Korkmaz IH; Niessen HW; Klein P; van Slegtenhorst M; Schinkel AF; Michels M; van Rossum AC; Germans T; van der Velden J
Eur J Clin Invest; 2015 Dec; 45(12):1252-9. PubMed ID: 26444145
[TBL] [Abstract][Full Text] [Related]
7. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
[TBL] [Abstract][Full Text] [Related]
8. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations.
Olivotto I; Girolami F; Sciagrà R; Ackerman MJ; Sotgia B; Bos JM; Nistri S; Sgalambro A; Grifoni C; Torricelli F; Camici PG; Cecchi F
J Am Coll Cardiol; 2011 Aug; 58(8):839-48. PubMed ID: 21835320
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.
Sedaghat-Hamedani F; Kayvanpour E; Tugrul OF; Lai A; Amr A; Haas J; Proctor T; Ehlermann P; Jensen K; Katus HA; Meder B
Clin Res Cardiol; 2018 Jan; 107(1):30-41. PubMed ID: 28840316
[TBL] [Abstract][Full Text] [Related]
10. Expression patterns of cardiac myofilament proteins: genomic and protein analysis of surgical myectomy tissue from patients with obstructive hypertrophic cardiomyopathy.
Theis JL; Bos JM; Theis JD; Miller DV; Dearani JA; Schaff HV; Gersh BJ; Ommen SR; Moss RL; Ackerman MJ
Circ Heart Fail; 2009 Jul; 2(4):325-33. PubMed ID: 19808356
[TBL] [Abstract][Full Text] [Related]
11. Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy.
Schuldt M; Pei J; Harakalova M; Dorsch LM; Schlossarek S; Mokry M; Knol JC; Pham TV; Schelfhorst T; Piersma SR; Dos Remedios C; Dalinghaus M; Michels M; Asselbergs FW; Moutin MJ; Carrier L; Jimenez CR; van der Velden J; Kuster DWD
Circ Heart Fail; 2021 Jan; 14(1):e007022. PubMed ID: 33430602
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models.
Ferrantini C; Coppini R; Pioner JM; Gentile F; Tosi B; Mazzoni L; Scellini B; Piroddi N; Laurino A; Santini L; Spinelli V; Sacconi L; De Tombe P; Moore R; Tardiff J; Mugelli A; Olivotto I; Cerbai E; Tesi C; Poggesi C
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28735292
[TBL] [Abstract][Full Text] [Related]
13. Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy.
Toepfer CN; Garfinkel AC; Venturini G; Wakimoto H; Repetti G; Alamo L; Sharma A; Agarwal R; Ewoldt JK; Cloonan P; Letendre J; Lun M; Olivotto I; Colan S; Ashley E; Jacoby D; Michels M; Redwood CS; Watkins HC; Day SM; Staples JF; Padrón R; Chopra A; Ho CY; Chen CS; Pereira AC; Seidman JG; Seidman CE
Circulation; 2020 Mar; 141(10):828-842. PubMed ID: 31983222
[TBL] [Abstract][Full Text] [Related]
14. Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications.
Ingles J; Burns C; Bagnall RD; Lam L; Yeates L; Sarina T; Puranik R; Briffa T; Atherton JJ; Driscoll T; Semsarian C
Circ Cardiovasc Genet; 2017 Apr; 10(2):. PubMed ID: 28408708
[TBL] [Abstract][Full Text] [Related]
15. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy.
Witjas-Paalberends ER; Piroddi N; Stam K; van Dijk SJ; Oliviera VS; Ferrara C; Scellini B; Hazebroek M; ten Cate FJ; van Slegtenhorst M; dos Remedios C; Niessen HW; Tesi C; Stienen GJ; Heymans S; Michels M; Poggesi C; van der Velden J
Cardiovasc Res; 2013 Aug; 99(3):432-41. PubMed ID: 23674513
[TBL] [Abstract][Full Text] [Related]
16. Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy.
Vakrou S; Liu Y; Zhu L; Greenland GV; Simsek B; Hebl VB; Guan Y; Woldemichael K; Talbot CC; Aon MA; Fukunaga R; Abraham MR
Sci Rep; 2021 Jun; 11(1):13163. PubMed ID: 34162896
[TBL] [Abstract][Full Text] [Related]
17. Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy.
Chida A; Inai K; Sato H; Shimada E; Nishizawa T; Shimada M; Furutani M; Furutani Y; Kawamura Y; Sugimoto M; Ishihara J; Fujiwara M; Soga T; Kawana M; Fuji S; Tateno S; Kuraishi K; Kogaki S; Nishimura M; Ayusawa M; Ichida F; Yamazawa H; Matsuoka R; Nonoyama S; Nakanishi T
Heart Vessels; 2017 Jun; 32(6):700-707. PubMed ID: 27885498
[TBL] [Abstract][Full Text] [Related]
18. Genetic diagnosis of hypertrophic cardiomyopathy using mass spectrometry DNA arrays and high resolution melting.
Santos S; Lança V; Oliveira H; Branco P; Silveira L; Marques V; Brito D; Madeira H; Bicho M; Fernandes AR
Rev Port Cardiol; 2011 Jan; 30(1):7-18. PubMed ID: 21425739
[TBL] [Abstract][Full Text] [Related]
19. Troponin T and beta-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy.
Revera M; van der Merwe L; Heradien M; Goosen A; Corfield VA; Brink PA; Moolman-Smook JC
Cardiovasc Res; 2008 Mar; 77(4):687-94. PubMed ID: 18029407
[TBL] [Abstract][Full Text] [Related]
20. Mutation location of HCM-causing troponin T mutations defines the degree of myofilament dysfunction in human cardiomyocytes.
Schuldt M; Johnston JR; He H; Huurman R; Pei J; Harakalova M; Poggesi C; Michels M; Kuster DWD; Pinto JR; van der Velden J
J Mol Cell Cardiol; 2021 Jan; 150():77-90. PubMed ID: 33148509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
